Prevention of aHUS involves:
Atypical hemolytic uremic syndrome (aHUS) is a rare and complex blood disorder characterized by the formation of blood clots in small blood vessels throughout the body. It is a type of thrombotic microangiopathy (TMA) that can cause multi-organ dysfunction, including kidney failure. aHUS is distinct from typical hemolytic uremic syndrome (HUS), which is often caused by Shiga toxin-producing E. coli (STEC). atypical hemolytic syndrome
aHUS is a complex and rare blood disorder that requires prompt recognition and treatment. With a comprehensive understanding of the pathophysiology, risk factors, clinical features, diagnostic criteria, and treatment options, healthcare professionals can provide optimal care for patients with aHUS. coli (STEC)
Today, the standard of care involves C5 inhibitors. These monoclonal antibodies work by blocking the C5 protein in the complement cascade, effectively halting the immune system’s attack on blood vessels. These therapies have revolutionized the prognosis for aHUS patients, often allowing for the recovery of kidney function and preventing the need for long-term dialysis. Living with a Rare Disease Today, the standard of care involves C5 inhibitors
Future work must focus on biomarker-driven monitoring (e.g., circulating C5b-9, genetic risk scores), development of orally available proximal pathway inhibitors, and global registries to track long-term outcomes. For now, any patient with unexplained TMA, especially without diarrhea or severe ADAMTS13 deficiency, deserves rapid consideration of aHUS and discussion with a complement expert.